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Abstract
Introduction: Henoch-Schönlein purpura is a common immunoglobulin A-mediated vasculitis syndrome in
children. Henoch-Schönlein purpura can also affect adults and is probably related to malignancy.
Case presentation: We report the case of a 61-year-old Japanese man who presented for examination after an
abnormal shadow was detected by chest radiography. He received a diagnosis of pulmonary adenocarcinoma,
stage IV. Purpura on the legs, abdominal pain, diarrhea, hematuria and proteinuria developed at this time. Henoch-
Schönlein purpura was diagnosed, base on the clinical symptoms and histological findings of biopsy specimens of
the skin, which showed vasculitis with immunoglobulin A deposits. Our patient received chemotherapy with
gemcitabine after successful steroid therapy for the Henoch-Schönlein purpura.
Conclusion: Although hematological malignancies are well-known causes of vasculitides, cases of Henoch-
Schönlein purpura associated with lung adenocarcinoma are rare. Our patient was treated with corticosteroid
therapy, which cleared the purpura and cytotoxic chemotherapy for the non-small cell lung cancer. However, he
died from heart failure due to cardiac tamponade.
Introduction
Henoch-Schönlein Purpura (HSP) is a systemic vasculitis
that involves the small vessels, most notably those in the
skin, gastrointestinal tract and glomeruli, and is accom-
panied by arthralgia or arthritis [1]. HSP occurs com-
monly in children but can also affect adults [2].
Although the exact cause of HSP remains unknown,
malignancy has been reported as a causative factor
[3-5]. This report illustrates a rare case of HSP asso-
ciated with pulmonary adenocarcinoma.
Case Presentation
A 61-year-old Japanese man presented for examination
after an abnormal lung shadow was detected during
population-based radiological screening. He was a cur-
rent smoker with a 41 pack-year smoking history. Chest
computed tomography (CT) showed a mass measuring
60 × 50 mm in the left upper lobe, with small nodules
in both lung fields and left pleura, and mediastinal and
subclavicular lymphadenopathy (Figure 1). Broncho-
scopy revealed stenosis of the left B3 bronchus with
mucosal abnormalities at points from which biopsy spe-
cimens were obtained. Cerebral magnetic resonance
imaging (MRI) demonstrated multiple brain metastases.
The final oncological diagnosis was a stage IV adenocar-
cinoma (T4N3M1b) without epidermal growth factor
receptor gene mutation. After stereotactic radiosurgery
for brain metastases, carried out in another hospital, our
patient was referred to us to receive chemotherapy.
On admission, our patient had progressive abdominal
pain, diarrhea and purpuric rash on the legs, which had
developed over the previous month. He was not taking
any medication. The abdomen was soft and flat with
minor tenderness. Palpable purpura was present on both
legs. His Eastern Cooperative Oncology Group perfor-
mance status was 1. His hematologic and blood chemi-
cal values were: white blood cell count of 9530/mm
3,a
hemoglobin concentration of 11.2 g/dL, an erythrocyte
sedimentation rate of 83 mm/hour, 6.52 mg/dL serum
C-reactive protein, >55U/mL CH50, 132 mg/dL C3, 37.7
mg/dL C4, 10.7 μg/dL D-dimer and 694 mg/dL fibrino-
gen (normal 160-400). Urine analysis showed proteinuria
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high-power field. Stool examination for occult blood
was positive. The findings were normal or negative for
platelet count, prothrombin time, activated partial
thromboplastin time, transaminases, creatinine, anti-
streptolysin O, rheumatoid factor (RF), antinuclear anti-
body (ANA), IgA, antineutrophil cytoplasmic antibody
(ANCA), cryoglobulin, rapid plasma regain, hepatitis B
surface antigen (HBsAg), hepatitis C virus (HCV) anti-
body and human immunodeficiency virus antibody.
Blood, urine and sputum cultures were negative.
Abdominal CT revealed diffuse swelling and thickening
of the small intestine walls and an absence of metastases
(Figure 2). Enteroscopy demonstrated multiple erosions
and ulcers of the intestine. A biopsy taken from the
intestinal mucus showed non-specific chronic inflamma-
tion without evidence of vasculitis. On histopathologic
examination of the palpable purpura, vasculitis was
seen, with infiltration of polymorphonuclear cells into
the vessel walls of the subpapillar plexus under the epi-
dermis (Figure 3AB). Immunofluorescent studies of the
biopsy specimen revealed deposition of IgA without C3
in superficial blood vessels (Figure 3C).
Our patient was diagnosed with HSP. Treatment with
prednisolone 0.8 mg/kg/day was initiated following dete-
rioration of renal function, as evidenced by a drop in
creatinine clearance from 82 mL/min at the time of
admission to 27 mL/min before starting prednisolone.
The clinical features of HSP, including abdominal pain
and skin rash, resolved within a week. Creatinine clear-
ance improved to 46 mL/min four weeks after the start
of steroid treatment. Prednisolone was tapered and
maintained at 0.6 mg/kg/day. Our patient received two
cycles of chemotherapy with gemcitabine 1000 mg/m
2
Figure 1 Computed tomography (CT) scan of the chest on admission to our hospital. Tumor in the left upper lobe, swelling of mediastinal
lymph nodes, and small nodules in both lung fields and pleura (arrows).
Figure 2 Computed tomography (CT) scan of the abdomen and pelvis on admission to our hospital. No evidence of metastasis but did
identify diffuse swelling and thickening of the small intestine walls (arrows).
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cycle. HSP was well controlled, and no other adverse
events were observed during chemotherapy. Two
months after of the start of chemotherapy, the patient
developed rapidly progressing dyspnea and hypoxia.
Chest CT and cardiac ultrasonography identified tumor
invasion of the pericardium and massive pericardial effu-
sion. Cytological examination of the pericardial effusion
revealed adenocarcinoma cells. Our patient was diag-
nosed with heart failure due to cardiac tamponade, and
twice underwent surgical drainage of the pericardial
effusion. His general condition gradually deteriorated
with disease progression, and he died three months after
the onset of HSP.
Discussion
HSP is a systemic vasculitis with IgA-dominant immune
deposits affecting small vessels, especially those in the
skin, gastrointestinal tract and kidney, and is accompa-
nied by arthralgia or arthritis [1]. HSP occurs more
commonly in children. The clinical presentation of HSP
is more severe in adults than in children, and the out-
come in adults is relatively poor [2].
T h ed i a g n o s t i cc r i t e r i af o rH S Pb yt h eA m e r i c a nC o l -
lege of Rheumatology are: palpable purpura, patient
aged ≤20 years; bowel angina, and granulocytes in the
walls of small arterioles or venules seen on biopsy. The
presence of two or more of these criteria has a sensitiv-
ity and specificity of 87.1% and 87.7%, respectively [6].
Our case met three of the four criteria, with the excep-
tion of age. Other vasculitides were highly unlikely
because markers for other systemic vasculitides (anti-
streptolysin O, RF, ANA, ANCA, cryoglobulin, rapid
p l a s m ar e g a i n ,H B s A g ,H C V )w e r ea l ln e g a t i v e .M o r e -
over, immunofluorescent studies of the biopsied skin
specimen showed IgA deposition in blood vessels. These
findings confirmed HSP. Novák et al. reported that vas-
culitic endoscopic lesions had been documented in only
some patients with HSP with abdominal symptoms [7].
Their findings may explain the finding in our patient’s
intestinal specimen of non-specific chronic inflammation
without vasculitis.
The occurrence of vasculitis in patients with malig-
nancy has been estimated at one in 1800 for hematologi-
cal malignancies and one in 80,800 for solid tumors [3].
HSP represents only 5% of vasculitis cases associated
with malignancy [4]. Although hematological malignan-
cies were more common than solid tumors in all types of
vasculitis, solid tumors were more common in associa-
tion with HSP [5]. Mitsui et al.r e p o r t e dt h a t2 3o f5 3
patients with HSP (43.4%) aged >40 years had underlying
malignancies [8]. The etiology of HSP remains obscure,
and various triggers, including bacterial or viral infec-
tions, foods and drugs, have been hypothesized. Adult
Figure 3 Histopathology of the palpable purpura. (A) Cellular infiltration into the obscured small vessel walls of the subpapillar plexus under
the epidermis (hematoxylin and eosin, original magnification × 100). (B) Infiltration of polymorphonuclear cells (haematoxylin and eosin, original
magnification × 150) (C) Fluorescent immunoglobulin A deposits (arrows) (original magnification × 100).
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cies, especially in the absence of these triggers [8].
Lung cancer is the most common solid malignancy
associated with HSP. Twelve cases of lung cancer pre-
senting with HSP have been reported to date, including
this one (Table 1) [9-18]. Mean patient age was 64.9
years (range 50-79 years) and all patients were men.
The most common lung-cancer histological diagnoses
were squamous cell (n = 7), adenocarcinoma (n = 3)
and small cell (n = 2). In six cases, the diagnosis of both
processes was simultaneous, and in four cases, HSP
antedated lung cancer by an average of 9.2 months
(range five-22 months). Lung cancer did not antedate
HSP in any of the cases. All patients had palpable pur-
pura and renal involvement, 55% of patients had gastro-
intestinal symptoms and 64% had joint involvement. In
the case reported here, there were no identifiable trig-
gers for the onset of HSP other than the malignancy
itself. The diagnosis of malignancy and the onset of HSP
occurred at the same time, therefore we believe that the
HSP was associated with the malignancy.
Treatment for patients with HSP and lung cancer is
also summarized in Table 1. Therapies for lung cancer
induced remission of HSP in some cases [9,10,15,16],
whereas other case reports indicated that corticosteroid
therapy was required for improvement of HSP
[11,14,17,18], as with our case. Our patient had an East-
ern Cooperative Oncology Group performance status of
1, and after treatment of the HSP to correct the progres-
sive renal insufficiency, there was no contraindication for
chemotherapy. Corticosteroid therapy obviously contrib-
uted to the improvement of the HSP and safe chemother-
apy. Unfortunately, the patient did not respond to
chemotherapy and died from causes associated with the
underlying cancer. Mitsui et al. found a correlation
between the development of HSP and poor prognosis of
malignancies [8]. They reported that seven of nine
patients with HSP and malignancies exhibited new meta-
static lesions or died of cancer within one-32 months
from the onset of HSP.
Conclusion
We report a rare case of HSP associated with non-small
cell lung cancer. To the best of our knowledge, this is
only the third case of HSP presenting with pulmonary
adenocarcinoma. Although the optimum treatment of
HSP with malignancy remains unclear, corticosteroid
therapy dramatically improved our patient’sc l i n i c a l
symptoms, and contributed to the management of his
lung cancer.
Consent
Written informed consent was obtained from the
patient’s spouse for publication of this case report and
any accompanying images. A copy of the written con-
sent is available for review by the Editor-in-Chief of this
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Table 1 Patients with Henoch-Schönlein purpura and lung cancer
Author Histology Occurrence of vasculitis in relation to
tumor
HSP therapy Malignancy therapy
Cairns [9] Squamous eight months before tumor Not done None
Squamous Synchronous
a Not done Surgical resection
Maurice [10] Squamous Synchronous Not done Surgical resection
Mitchell [11] Squamous 22 months before tumor Prednisone + azathioprine Surgical resection
Pfitzenmeyer
[12]
Squamous six months before tumor Not done None
Gutiérrez [13] Squamous Synchronous Not available Not available
Frigui [14] Squamous six months before tumor Methylprednisolone pulses, prednisone Chemotherapy,
radiotherapy
Blanco R [15] Small cell Synchronous Not done Chemotherapy
Ponge T [16] Small cell eight months before tumor Not done Chemotherapy
Weiler-Bisig [17] Adenocarcinoma five months before tumor Prednisolone Chemotherapy
Salon [18] Adenocarcinoma Synchronous Prednisone + intravenous
gammaglobulins
Surgical resection
Present case Adenocarcinoma Synchronous Prednisolone Chemotherapy
aSynchronous: within 1 month of cancer diagnosis.
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